Alzheimer's disease (AD), the leading cause of dementia worldwide, is characterized by the
accumulation of the β-amyloid peptide (Aβ) within the brain along with hyperphosphorylated …

Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most
common cause of dementia with an estimated prevalence of 30 million people worldwide, a …

Lipid-mediated signalling regulates a plethora of physiological processes, including crucial
aspects of brain function. In addition, dysregulation of lipid pathways has been implicated in …

Amyloid-β (Aβ) plaque deposition in specific brain regions is a pathological hallmark of
Alzheimer's disease. However, the mechanism underlying the regional vulnerability to Aβ …

Alzheimer's disease (AD), the most common neurodegenerative disorder, is a growing
public health problem and still lacks effective treatments. Recent evidence suggests that …

Epidemiological, neuropathological, and functional neuroimaging evidence implicates
global and regional disruptions in brain metabolism and energetics in the pathogenesis of …

Alzheimer's disease constitutes a personal and societal tragedy of immense proportions.
Since 1960, research in laboratories and clinics worldwide has elucidated many features of …

Amyloid-β oligomers may cause cognitive deficits in Alzheimer's disease by impairing
neuronal NMDA-type glutamate receptors, whose function is regulated by the receptor …

Aggregation of amyloid-β (Aβ) as toxic oligomers and amyloid plaques within the brain
appears to be the pathogenic event that initiates Alzheimer's disease (AD) lesions. One …

Objective: The goal of this study was to investigate the role of endogenous amyloid‐β
peptide (Aβ) in healthy brain. Methods: Long‐term potentiation (LTP), a type of synaptic …